I have spent my career caring for patients with chronic pain, dementia and other conditions that drain not only quality of life but also the healthcare system’s resources. Too often, I’ve prescribed medications that are costly and dangerous and carry high risks of dependency and death.

There is another option many of my patients already use: medical cannabis. The plant is one of the most effective and safest treatments for a host of chronic conditions.

Yet, every day, patients must choose between paying rent or paying out of pocket for cannabis because insurance companies refuse to cover it. Insurance coverage for medical cannabis is not a radical idea. It is the next logical step.

We face two epidemics quietly sinking our healthcare system: chronic pain and dementia. Together, these conditions consume a staggering share of Medicare and Medicaid budgets.

They also drive patients toward the drugs fueling our overdose crisis.

Cannabis can be an exit strategy. Studies show 30 percent to 50% reductions in opioid use when patients substitute with cannabis. Unlike opioids or benzodiazepines, cannabis has no recorded overdose deaths. Broader adoption could save as many as 50,000 lives annually.

For patients with dementia, cannabis improves sleep, appetite, mood and agitation symptoms — often allowing them to reduce or stop medications that have debilitating side effects.

The oft-heard claim that cannabis “lacks data” is outdated. A comprehensive research review by the National Academies of Sciences, Engineering and Medicine in 2017 classified cannabis as an evidence-based treatment for chronic pain, multiple sclerosis and chemotherapy-related nausea.

Research has expanded since then, with international models from Israel to Canada demonstrating measurable benefits and cost savings.

We also have growing patient-reported outcomes — structured data gathered directly from people using cannabis. These outcomes capture what clinical trials often miss — improvements in daily functioning, sleep, mood and overall quality of life.

Federal agencies are stuck in a catch-22: The Food and Drug Administration cannot approve cannabis because products vary batch-to-batch, and without FDA approval, insurers won’t cover it. Patients are left to rely on advice from poorly trained dispensary staff, pursue an unsupported trial-and-error approach, or go without entirely.

We already have models. Hospice programs, for example, receive a per-diem payment from Medicare to cover all palliative needs.

Integrative pain programs, such as those offered at the University of Vermont, are often approved for insurance reimbursement and have been shown to yield significant savings.

We should also explore Medicaid waivers, such as Section 1115 behavioral health, to allow cannabis coverage for chronic pain, anxiety and substance-use disorder.

Critics argue that cannabis is unsafe or that coverage would invite abuse. Most of those claims are based on recreational smoking and not carefully dosed, medical use.

Yes, cannabis is not appropriate for everyone, particularly adolescents. However, for adults, especially older adults, the benefits often far outweigh the risks. Financial cost is another hot topic. By reducing emergency room visits, imaging, physician appointments and dangerous drug interactions, insurance coverage would save money. Insurers are already paying for the consequences of chronic pain and dementia. Covering cannabis is in their financial interest.

Nearly 75% of U.S. adults live in states with legal cannabis access. We know cannabis works for many conditions. We know it’s safer than most alternatives. The data is growing, the public is ready and patients are demanding it. What we lack is political will.

Later this fall, experts will gather at the Society of Cannabis Clinicians’ Medical Cannabis Conference in Denver to share research and policy ideas — a fitting venue for the urgent conversation about insurance coverage.

As a physician, I cannot ignore treatments my patients are already using and benefiting from. Insurance companies should not ignore them either.

Covering medical cannabis is not just logical. It is ethical. It is necessary. And it will save lives.

_____

ABOUT THE WRITER

Mikhail Kogan is a co-author of “Medical Marijuana: Dr. Kogan’s Evidence-Based Guide to the Health Benefits of Cannabis and CBD” and associate professor of medicine and chief medical officer of the Center for Integrative Medicine at George Washington University. He wrote this for InsideSources.com.

_____

©2025 Tribune Content Agency, LLC